Does Rallies show 13F holders for GERN?

Yes. Rallies tracks hedge fund and 13F ownership data for GERN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is GERN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GERN. It does not provide personalized investment advice.

GERN (Geron Corp) Stock Analysis - Hedge Fund Holdings

Geron Corp (GERN) is a publicly traded Healthcare sector company. As of May 20, 2026, GERN trades at $1.25 with a market cap of $789.07M and a P/E ratio of -11.41. GERN moved +3.28% today. Year to date, GERN is -7.58%; over the trailing twelve months it is -12.23%. Its 52-week range spans $1.04 to $4.65. Analyst consensus is buy with an average price target of $3.25. Rallies surfaces GERN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns GERN stock?

Hedge funds tracked by Rallies that own GERN include Orbimed Advisors, Matrix Capital, Panagora Asset, Temasek Holdings, and Farallon Capital. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Geron Corp.

GERN Key Metrics

Key financial metrics for GERN
Metric	Value
Price	$1.25
Market Cap	$789.07M
P/E Ratio	-11.41
EPS	$-0.11
Dividend Yield	0.00%
52-Week High	$4.65
52-Week Low	$1.04
Volume	7.50M
Avg Volume	0
Revenue (TTM)	$196.12M
Net Income	$-67.31M
Gross Margin	0.00%

Top Hedge Funds Holding GERN

Orbimed Advisors holds 2.17M shares of GERN, changed -75.72% as of Dec 31, 2024.
Matrix Capital holds 571.50K shares of GERN, changed +0.00% as of Jun 30, 2024.
Panagora Asset holds 360.85K shares of GERN, changed +0.00% as of Mar 31, 2026.
Temasek Holdings holds 139.96K shares of GERN, changed +0.00% as of Sep 30, 2024.
Farallon Capital holds 43.00K shares of GERN, changed +0.00% as of Mar 31, 2026.

Latest GERN News

Geron to Present First Real-World RYTELO Data at EHA 2026 Congress — May 20, 2026
Geron Q1 Revenue Rises 8% to $51.8M, Net Loss Narrows to $3.6M — May 6, 2026
Geron Grants 2.5M Share Options at $1.73 Exercise Price with Four-Year Vesting — Apr 14, 2026
Geron Appoints Former Vanda GC Timothy Williams as Chief Legal Officer — Apr 13, 2026
Reblozyl Tops $2.3B Sales, Heightening Pressure on Geron’s Rytelo Growth — Mar 5, 2026

Recent GERN Insider Trades

ROBERTSON MICHELLE sold 9.86K (~$19.12K) on Feb 18, 2026.
LAWLIS V BRYAN bought 13.30K (~$15.67K) on May 9, 2025.
Samuels Scott Alan bought 15.00K (~$24.15K) on Feb 27, 2025.

GERN Analyst Consensus

5 analysts cover GERN: 0 strong buy, 3 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.25.

Common questions about GERN

Who owns GERN stock?: Hedge funds tracked by Rallies that own GERN include Orbimed Advisors, Matrix Capital, Panagora Asset, Temasek Holdings, and Farallon Capital. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Geron Corp.
Does Rallies show 13F holders for GERN?: Yes. Rallies tracks hedge fund and 13F ownership data for GERN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is GERN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GERN. It does not provide personalized investment advice.